Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of [131I]ICF01012 in Metastatic Melanoma
NCT03784625Phase 1Completed
- Sponsor
- Centre Jean Perrin
- Start
- Oct 2019
- Primary completion
- Jan 2025
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label trial of [131I]ICF01012 in melanoma (4 arms), sponsored by Centre Jean Perrin. Primary endpoint: Dose-Limiting Toxicities at 6 weeks. Started Oct 2019; status: completed.
02
Drugs
[131I]ICF01012
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03784625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03784625.